Fig. 3

Forest plot of carfilzomib exposure PK parameter ratios and 90% CI following IV administration of carfilzomib *. Horizontal axis shows the fold change in AUC_0–last and AUC_0–inf, relative to the normal hepatic function group. * Excludes 1 outlier patient from normal hepatic function group at the carfilzomib 56 mg/m² dose. AUC _0–inf time 0 extrapolated to infinity, AUC _0–last time 0 to time of last concentration measured, CI confidence interval, IV intravenous, PK pharmacokinetic